Arcturus Therapeutics In Deal With Johnson & Johnson Innovation

San Diego-based RNA therapeutics developer Arcturus Therapeutics announced this morning that it is in a strategic collaboration deal, with Johnson & Johnson Innovation. The company said it has entered into a worldwide license agreement with Janssen Pharmaceuticals to develop and commercialize RNA-based drug products for specified diseases, using Arcturus' platform and technology. Financial terms of the deal were not disclosed, however, Arcturus said it will receive an upfront payment, R&D support, and pre-clinical, development and sales milestone payments, as well as royalties on future product sales. Plus, Janssen will assume responsibility for development and commercialization costs associated with the new program.